On Thursday, Shares of Netflix, Inc. (NASDAQ:NFLX), gained 0.30% to $99.48.
Netflix declared it will expand into South Korea, Singapore, Hong Kong and Taiwan in early 2016 as it moves to complete its global rollout by the end of next year.
Once launched, Internet users will be able to subscribe to Netflix and instantly watch a curated selection of popular TV shows and movies in high-definition or even Ultra HD 4K on nearly any Internet-connected screen. Netflix first became available in Asia earlier this month with the start of service in Japan.
“The combination of increasing Internet speeds and ubiquity of connected devices provides consumers with the anytime, anywhere ability to enjoy their favorite TV shows and movies on the Netflix service,” said Reed Hastings, chief executive officer of Netflix. “These four markets well represent those trends.”
With a constantly improving user experience, advanced personalization technology and a curated selection of TV shows and films, Netflix members are able to create their own viewing experience and can easily discover new favorites, while reconnecting with popular characters and stories.
Netflix, Inc., an Internet television network, engages in the Internet delivery of TV shows and movies directly on TVs, computers, and mobile devices in the United States and internationally. The company operates in three segments: Domestic Streaming, International Streaming, and Domestic DVD.
Shares of The Dow Chemical Company (NYSE:DOW), declined -0.07% to $43.76, during its last trading session.
The Dow Chemical Company was named to the Dow Jones Sustainability World Index as one of the top performers in the global chemical industry, marking the 15th time Dow has received this recognition since the launch of the index. This year’s declaration ties Dow as the longest-standing representative in the chemical category since the list’s inception in 1999.
With only 10 chemical companies named to the World Index in 2015, Dow is proud to be recognized for sustainability performance in the top 10 percent of the chemical industry. In addition, Dow received a perfect score of 100 on the Climate Strategy and Customer Relationship Administration sections, demonstrating the Company’s unique strengths of working closely with customers to develop differentiated, science-based solutions to address today’s global challenges.
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments.
Finally, Novavax, Inc. (NASDAQ:NVAX), ended its last trade with -0.69% loss, and closed at $10.10.
Novavax declared that the full data set from its clinical trial of the RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of childbearing age (18-35 years) were published in the Journal of Infectious Disease. The Company formerly declared top-line results from the trial.
The manuscript describes the randomized, blinded, placebo-controlled Phase 2 clinical trial that evaluated the safety and immunogenicity of two dose levels of the RSV F Vaccine with and without aluminum phosphate adjuvant. The trial enrolled 330 women of childbearing age who received either one or two intramuscular injections of a single-dose (60 or 90 µg) of vaccine or placebo at study days 0 and 28.
The manuscript details the noteworthy antibody response to the RSV F Vaccine counting a 6.5-15.6-fold improvement in anti-F IgG antibodies across all vaccine doses at day 56, with significantly higher levels in the two-dose adjuvanted regimens. Palivizumab-competing antibody (PCA) levels were undetectable at day 0 but raised up to between 205-325 µg/mL at day 56. Further, a 2.7 and 3.5-fold rise in RSV/A and RSV/B microneutralizing antibodies were detected at day 56, before the RSV season. Finally, between days 56 and 112, 21% (12/56) of placebo recipients showed evidence of a recent RSV infection by Western Blot contrast to 11% of vaccinees (26/244) (p = 0.04).
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
